Table 1.

Cotreatment with TQ and ruxolitinib, OTX015, or pelabresib (CPI0610) exerted synergistic lethality against PD post-MPN sAML cells

Combination agentTQ
5 μM10 μM20 μM
Ruxolitinib    
250 nM 5.604 1.308 6.535 
500 nM 3.912 5.400 4.598 
1000 nM 8.245 5.736 9.062 
OTX015    
50 nM 2.562 3.206 4.540 
100 nM 1.603 2.629 2.806 
250 nM 4.041 3.840 3.838 
Pelabresib    
100 nM 2.245 7.082 12.276 
250 nM 5.561 7.764 20.382 
500 nM 2.110 3.558 20.232 
Combination agentTQ
5 μM10 μM20 μM
Ruxolitinib    
250 nM 5.604 1.308 6.535 
500 nM 3.912 5.400 4.598 
1000 nM 8.245 5.736 9.062 
OTX015    
50 nM 2.562 3.206 4.540 
100 nM 1.603 2.629 2.806 
250 nM 4.041 3.840 3.838 
Pelabresib    
100 nM 2.245 7.082 12.276 
250 nM 5.561 7.764 20.382 
500 nM 2.110 3.558 20.232 

Table shows delta synergy scores for the combination agents with TQ at the doses listed in 3 PD post-MPN sAML cells. Delta synergy scores (ZIP method) of TQ concentrations in PD sAML cells (n = 3).

or Create an Account

Close Modal
Close Modal